Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRMD CorMedix	$14.34 +1.4%	$12.28	$5.31 ▼ $17.43	$1.07B	1.71	1.97 million shs	3.87 million shs
CRON Cronos Group	$2.59 +1.2%	$2.16	$1.60 ▼ $2.77	$992.46M	1.01	1.87 million shs	5.21 million shs
IMMP Prima BioMed	$1.67 +0.6%	$1.69	$1.32 ▼ $2.72	$245.13M	1.66	156,266 shs	44,863 shs
PRAX Praxis Precision Medicines	$45.98 -2.0%	$49.05	$26.70 ▼ $91.83	$967.80M	2.62	447,164 shs	121,345 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRMD CorMedix	+1.07%	+4.59%	+18.03%	+15.71%	+129.17%
CRON Cronos Group	+0.39%	+5.79%	+24.27%	+24.88%	+16.36%
IMMP Prima BioMed	-1.78%	0.00%	-7.78%	-15.74%	-30.54%
PRAX Praxis Precision Medicines	-2.05%	+3.69%	-15.69%	+22.03%	-12.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRMD CorMedix	2.7079 of 5 stars	3.4	1.0	3.8	0.0	1.9
CRON Cronos Group	0.7843 of 5 stars	0.0	3.0	2.5	0.0	1.3
IMMP Prima BioMed	1.5152 of 5 stars	3.5	1.0	3.3	0.0	0.0
PRAX Praxis Precision Medicines	1.6927 of 5 stars	3.4	1.0	2.7	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRMD CorMedix	2.86	Moderate Buy	$17.33	20.87% Upside
CRON Cronos Group	0.00	N/A	N/A	N/A
IMMP Prima BioMed	3.00	Buy	$7.00	319.16% Upside
PRAX Praxis Precision Medicines	2.75	Moderate Buy	$85.88	86.78% Upside

Current Analyst Ratings Breakdown

Latest IMMP, PRAX, CRMD, and CRON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	CRMD CorMedix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $17.00
8/5/2025	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00 ➝ $115.00
7/29/2025	PRAX Praxis Precision Medicines	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
7/18/2025	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00
7/8/2025	PRAX Praxis Precision Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$97.00 ➝ $115.00
6/30/2025	CRMD CorMedix	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/30/2025	CRMD CorMedix	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
6/30/2025	CRMD CorMedix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00
6/24/2025	CRMD CorMedix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $20.00
6/23/2025	CRMD CorMedix	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
6/20/2025	CRMD CorMedix	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$13.00 ➝ $17.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRMD CorMedix	$43.47M	24.63	N/A	N/A	$2.96 per share	4.84
CRON Cronos Group	$117.61M	8.44	$0.00 per share	5,480.10	$2.95 per share	0.88
IMMP Prima BioMed	N/A	N/A	N/A	N/A	$1.05 per share	N/A
PRAX Praxis Precision Medicines	$8.55M	113.19	N/A	N/A	$19.21 per share	2.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRMD CorMedix	-$17.93M	$0.75	19.12	15.26	N/A	42.11%	42.73%	34.19%	10/29/2025 (Estimated)
CRON Cronos Group	$41.08M	$0.05	51.82	86.37	N/A	14.19%	-3.78%	-3.62%	11/11/2025 (Estimated)
IMMP Prima BioMed	-$28.01M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/29/2025 (Estimated)
PRAX Praxis Precision Medicines	-$182.82M	-$12.29	N/A	N/A	N/A	-2,137.48%	-60.07%	-54.84%	11/5/2025 (Estimated)

Latest IMMP, PRAX, CRMD, and CRON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	CRMD CorMedix	$0.20	$0.28	+$0.08	$0.28	$29.88 million	$39.74 million
8/7/2025	Q2 2025	CRON Cronos Group	-$0.02	-$0.10	-$0.08	-$0.10	$45.73 million	$33.46 million
8/4/2025	Q2 2025 & Study Result	PRAX Praxis Precision Medicines	-$3.40	-$3.31	+$0.09	-$3.31	$0.15 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
IMMP Prima BioMed	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRMD CorMedix	N/A	7.82	7.52
CRON Cronos Group	N/A	24.65	23.53
IMMP Prima BioMed	N/A	18.86	N/A
PRAX Praxis Precision Medicines	N/A	6.31	6.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRMD CorMedix	34.18%
CRON Cronos Group	8.71%
IMMP Prima BioMed	2.32%
PRAX Praxis Precision Medicines	67.84%

Insider Ownership

Company	Insider Ownership
CRMD CorMedix	5.30%
CRON Cronos Group	7.30%
IMMP Prima BioMed	3.07%
PRAX Praxis Precision Medicines	2.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRMD CorMedix	30	74.65 million	70.69 million	Optionable
CRON Cronos Group	450	383.04 million	355.08 million	Optionable
IMMP Prima BioMed	2,021	146.79 million	142.28 million	Optionable
PRAX Praxis Precision Medicines	110	21.05 million	20.48 million	Optionable

IMMP, PRAX, CRMD, and CRON Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX

August 27 at 10:00 AM | prnewswire.com

Candriam S.C.A. Lowers Holdings in Praxis Precision Medicines, Inc. $PRAX

August 26 at 4:49 AM | marketbeat.com

Algert Global LLC Invests $814,000 in Praxis Precision Medicines, Inc. $PRAX

August 26 at 4:05 AM | marketbeat.com

Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline

August 25 at 4:01 PM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX

August 25 at 12:13 PM | globenewswire.com

PRAXIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Praxis Precision Medicines, Inc. on Behalf of Praxis Stockholders and Encourages Investors to Contact the Firm

August 23, 2025 | globenewswire.com

Aberdeen Group plc Increases Stock Position in Praxis Precision Medicines, Inc. $PRAX

August 23, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX

August 22, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX

August 21, 2025 | globenewswire.com

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives $85.88 Consensus PT from Analysts

August 20, 2025 | americanbankingnews.com

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Recommendation of "Moderate Buy" by Brokerages

August 18, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX

August 17, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX

August 16, 2025 | prnewswire.com

Protect Your Investment: Contact Levi & Korsinsky About the Praxis Precision Medicines, Inc. (PRAX) Investigation

August 14, 2025 | theglobeandmail.com

PRAX Investors Have Opportunity to Join Praxis Precision Medicines, Inc. ...

August 14, 2025 | gurufocus.com

PRAX Investors Have Opportunity to Join Praxis Precision Medicines, Inc. Fraud Investigation with the Schall Law Firm

August 14, 2025 | prnewswire.com

PRAX Investors Have Opportunity to Join Praxis Precision Medicines, Inc. Fraud Investigation with the Schall Law Firm

August 13, 2025 | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX

August 13, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX

August 11, 2025 | prnewswire.com

Chardan Capital Brokers Lower Earnings Estimates for PRAX

August 11, 2025 | marketbeat.com

XTX Topco Ltd Purchases Shares of 10,043 Praxis Precision Medicines, Inc. (NASDAQ:PRAX)

August 10, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMP, PRAX, CRMD, and CRON Company Descriptions

CorMedix NASDAQ:CRMD

$14.34 +0.20 (+1.41%)

Closing price 03:59 PM Eastern

Extended Trading

$14.35 +0.01 (+0.07%)

As of 04:04 PM Eastern

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Cronos Group NASDAQ:CRON

$2.59 +0.03 (+1.21%)

Closing price 03:59 PM Eastern

Extended Trading

$2.60 +0.01 (+0.35%)

As of 04:04 PM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Prima BioMed NASDAQ:IMMP

$1.67 +0.01 (+0.60%)

Closing price 03:58 PM Eastern

Extended Trading

$1.67 0.00 (0.00%)

As of 04:04 PM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Praxis Precision Medicines NASDAQ:PRAX

$45.98 -0.94 (-2.01%)

Closing price 03:59 PM Eastern

Extended Trading

$46.02 +0.04 (+0.08%)

As of 04:04 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time